Ambrx Biopharma Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ambrx Biopharma Inc (NYSE:AMAM) Given Consensus Rating of Moderate Buy by Analysts

Ambrx Biopharma Inc (NYSE:AMAM) Given Consensus Rating of Moderate Buy by Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdAmbrx biopharmaRenaissance technologiesAmbrx biopharma incB riley wealth advisors incRoyal bankCantor fitzgeraldAmbrx biopharma company profileGet free reportMarketbeat ratingsWealth advisorsExoduspoint capital managementGet freeBiopharma incAmbrx biopharma daily

Ambrx Biopharma Inc (NYSE:AMAM) Receives $24 13 Consensus Price Target from Brokerages

Ambrx Biopharma Inc (NYSE:AMAM) Receives $24 13 Consensus Price Target from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Ambrx biopharmaRobertw bairdCantor fitzgeraldHighvista strategiesAmbrx biopharma incRoyal bankSilverarc capital managementAmbrx biopharma company profileTd asset management incGet free reportMarketbeat ratingsBiopharma stock downManagement incPoint capital managementVista strategiesAsset management

Ambrx Biopharma Inc (NYSE:AMAM) Given Consensus Rating of Moderate Buy by Analysts

Ambrx biopharmaRobertw bairdExchange traded conceptsGoldman sachs groupInnovis asset managementRoyal bankChina universal asset management coSquarepoint opsAmbrx biopharma incAmbrx biopharma company profileGet free reportUniversal asset managementTraded conceptsAsset managementExoduspoint capital managementBiopharma stock down

Ambrx Biopharma (NYSE:AMAM) vs Gilead Sciences (NASDAQ:GILD) Head-To-Head Contrast

Ambrx Biopharma (NYSE:AMAM – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Profitability This table compares Ambrx Biopharma and Gilead […]

United statesLa jollaFoster cityComplera evipleraAmbrx biopharmaAssembly biosciences incGilead sciences incJapan tobacco incArcus biosciences incPionyr immunotherapeutics incTherapeutics incMerck co incJounce therapeutics incTentarix biotherapeutics incAmbrx biopharma incTango therapeutics inc

Ambrx Biopharma (NYSE:AMAM) Downgraded by B Riley to Neutral

B. Riley lowered shares of Ambrx Biopharma (NYSE:AMAM – Free Report) from a buy rating to a neutral rating in a research note released on Tuesday, MarketBeat Ratings reports. B. Riley currently has $28.00 price objective on the stock, up from their previous price objective of $26.00. A number of other analysts have also weighed […]

Ambrx biopharmaSonja nelsonGoldman sachs groupCantor fitzgeraldHermes incSecurities exchange commissionDarwin global management ltdRoyal bankAmbrx biopharma incFree reportMarketbeat ratingsModerate buyBiopharma trading downCormorant asset managementExchange commissionGlobal management